PCM Trials announced that it acquired EmVenio Research, marking its second acquisition of 2024.
Emvenio is a research organization providing scalable and hybrid decentralized trial solutions with a focus on improving access and health equity in clinical research. EmVenio is a community clinical trial provider that incorporates mobile research units to increase reach to underserved communities. EmVenio has 63 mobile sites for studies in more than 20 states across the United States and 10 locations in the United Kingdom. According to EmVenio, its sites are seeing greater than 50% diverse patients across all locations compared with the industry average of less than 20%. The company’s participant retention rate is at nearly 97%.
PCM Trials is a provider of mobile research nurses for decentralized clinical trials. It is headquartered in Denver, Colorado, with European operations based out of the United Kingdom. The company has conducted mobile research visits since 2008. PCM Trials has approximately 325 full-time employees in Denver who manage roughly 1,000 trial nurses across the United States.
This acquisition will grant PCM Trials access to underserved community networks, the companies said in a news release. Financial terms of the deal were not disclosed. This acquisition follows PCM Trials’ recently announced acquisition of Netherlands-based Clinical Trial Service in January 2024.
Greg Austin, president of PCM Trials, noted that two latest acquisitions make PCM Trials “the largest and most experienced clinical research local access provider on a global scale.”
According to data captured in the LevinPro HC database, this acquisition marks the ninth clinical trials transaction of 2024. There were 42 clinical trials deals announced during 2023, a 40% increase from the 30 deals announced during 2022.
